87
Participants
Start Date
September 28, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
GS-0272
Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
Placebo
Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B)
RECRUITING
Ajou University Hospital, Suwon
COMPLETED
Altoona Center for Clinical Research, Duncansville
RECRUITING
PA Regional Center for Arthritis and Osteoporosis Research, Wyomissing
RECRUITING
Jacksonville Center for Clinical Research, Jacksonville
RECRUITING
Clinical Research of West Florida, Inc., Clearwater
RECRUITING
Chungnam National University Hospital, Daejeon
RECRUITING
1600 Republic Parkway, Mesquite
RECRUITING
Precision Comprehensive Clinical Research Solutions, Colleyville
RECRUITING
Accurate Clinical Research, Inc., Houston
RECRUITING
Arizona Arthritis & Rheumatology Associates P.C., Glendale
RECRUITING
1238 E. Arrow Hwy, Upland
RECRUITING
Stanford School of Medicine, Division of Immunology & Rheumatology, Palo Alto
RECRUITING
Summit Headlands LLC, Portland
RECRUITING
ARENSIA Exploratory Medicine LLC, Tbilisi
RECRUITING
"IMSP Republican Clinical Hospital Timofei Mosneaga, ARENSIA E.M.", Chisinau
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Cambridge Clinical Research Centre, Rheumatology Research Unit - E6, Addenbrookes Hospital, Cambridge
RECRUITING
Kings College Hospital, London
RECRUITING
Simbec Research Limited, Merthyr Tydfil
RECRUITING
NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton
Lead Sponsor
Gilead Sciences
INDUSTRY